compani
eli lilli lilli report result impress beat
analyst core ep expect guidanc fy core ep rais
mid-point rang
consensu upgrad base chang payer mix fx
lesser extent tax well import driver volum
nonetheless fundament busi still look good core ep
forecast rise fy smaller increment thereaft
lilli sale trajectori look healthi import chang outlin
believ still margin leverag realis price target
rise slightli
drug diabet portfolio deliv anoth good
quarter once-weekli agonist trulic lilli main growth
driver demand remain strong continu establish strong
base trulic vital novo nordisk launch competitor once-
weekli product ozemp humalog insulin also perform well although
mainli beat expect due favour us rebat
rais forecast trulic humalog
fast-grow psoriasi drug taltz miss expect
compani indic miss inventori
movement problem also affect rival novartiss sale cosentyx
first quarter underli basi howev sale also miss
trim forecast slightli constant currenc basi still
high hope product efficaci excel
follow contenti fda advisori committe ad com look
though pipelin rheumatoid arthriti ra drug baricitinib
approv us ad com vote approv dose
lilli want dose would like allow label
claim superior market-lead humira look
though compani push approv dose nich
popul allow dose wider popul success
mean assur previous remov us sale baricitinib
model add revenu back although assumpt
us sale trail behind ex-u sale dose approv europ
australia japan elsewher
elanco review process continu lilli previous state
review option futur elanco anim health busi
revenu timelin decis
unchang continu expect announc result
note howev compani announc hire new
elanco-specif cfo evid seen far point
toward elanco leav group
chang made note
buy chang
compani
perform rel
compani base us
global biopharmaceut
profit loss summari
growth margin
period patent expiri fall net incom lilli
return top-lin growth
key driver lilli futur growth rejuven diabet
franchis complet product portfolio previous
includ basal insulin offer class
believ lilli nearli doubl revenu
diabet
second driver rich late-stag pipelin
potenti deliv three blockbust drug area
psoriasi headach oncolog
margin also improv lilli invest start
pay term revenu
valuat dcf-deriv
chang net debt
average cost debt
risk invest thesi
pipelin might deliv potenti blockbust drug
identifi might either fail get market fail gain
traction
diabet franchis might threaten competitor product
space sooner
compani
collabor
collabor
collabor
collabor
compani
profit loss account
sale
 revenu
 revenu
incom tax
incom tax
incom tax
incom tax
account receiv net allow
pre-paid expens
goodwil intang net
total asset
total asset
total asset
total asset
properti equip net
short-term borrow current matur long-term debt
total liabilit
total liabilit
total liabilit
total liabilit
sharehold equiti
total liabil equiti
total liabil equiti
total liabil equiti
total liabil equiti
compani
net cash provid oper activ
net cash provid oper activ
net cash provid oper activ
net cash provid oper activ
addit dispos properti equip net
chang non-current invest net
purchas product right
purchas in-process
paid acquisit net cash acquir
net cash use invest activ
net cash use invest activ
net cash use invest activ
net cash use invest activ
net chang short-term borrow
proce issuanc long-term debt
repay long-term debt
puchas common stock
net cash use financ activ
net cash use financ activ
net cash use financ activ
net cash use financ activ
fx effect cash equival
 cash equival begin year
 cash equival end year
 cash equival end year
 cash equival end year
 cash equival end year
compani
pleas note use research report subject condit restrict set forth gener inv
pleas note use research report subject condit restrict set forth gener invest
pleas note use research report subject condit restrict set forth gener inv
pleas note use research report subject condit restrict set forth gener inv
disclosur legal disclaim end document
